Technical Analysis for CERS - Cerus Corporation

Grade Last Price % Change Price Change
grade B 5.9 0.85% 0.05
CERS closed up 0.85 percent on Friday, June 5, 2020, on approximately normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical CERS trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.85%
Overbought Stochastic Strength 0.85%
Down 3 Days in a Row Weakness 0.85%
Stochastic Sell Signal Bearish -7.38%
NR7 Range Contraction -7.38%
Upper Bollinger Band Walk Strength -7.38%
Inside Day Range Contraction -7.38%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company that focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company's INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. Its INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; and INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion. The company is also developing INTERCEPT Blood System for red blood cells, which is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets its platelet and plasma systems through its direct sales force and distributors primarily in Europe, the Commonwealth of Independent States, and the Middle East. The company has collaboration agreements with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Coronavirus Anatomy Blood Hematology Transfusion Medicine Blood Products Coagulation System Blood Transfusion Platelet Red Blood Cell

Is CERS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 6.6501
52 Week Low 2.71
Average Volume 1,820,778
200-Day Moving Average 4.78
50-Day Moving Average 5.42
20-Day Moving Average 5.76
10-Day Moving Average 6.12
Average True Range 0.36
ADX 20.61
+DI 25.75
-DI 22.86
Chandelier Exit (Long, 3 ATRs ) 5.57
Chandelier Exit (Short, 3 ATRs ) 6.13
Upper Bollinger Band 6.56
Lower Bollinger Band 4.96
Percent B (%b) 0.59
BandWidth 27.74
MACD Line 0.22
MACD Signal Line 0.22
MACD Histogram 0.0034
Fundamentals Value
Market Cap 643.9 Million
Num Shares 109 Million
EPS -0.61
Price-to-Earnings (P/E) Ratio -9.67
Price-to-Sales 8.39
Price-to-Book 7.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.65
Resistance 3 (R3) 6.67 6.45 6.53
Resistance 2 (R2) 6.45 6.26 6.44 6.48
Resistance 1 (R1) 6.17 6.14 6.06 6.15 6.44
Pivot Point 5.95 5.95 5.89 5.94 5.95
Support 1 (S1) 5.67 5.76 5.56 5.65 5.36
Support 2 (S2) 5.45 5.64 5.44 5.32
Support 3 (S3) 5.17 5.45 5.28
Support 4 (S4) 5.15